Clinicians' prescription preferences for treating patients with Alzheimer's disease in Shanghai. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Ban, Chun-Xia; Xiao, Shi-Fu; Lin, Xiang; Wang, Tao; Qiu, Qi; Zhu, Min-Jie; Li, Xia
• Is Part Of: Translational neurodegeneration. Volume 5:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: Alzheimer's disease -- Clinicians -- Cognitive enhancers -- Prescriptions -- Survey research; Nervous system -- Degeneration -- Periodicals; Nervous system -- Degeneration -- Treatment -- Periodicals; Nerve Degeneration -- Periodicals; 616.8
• DOI: 10.1186/s40035-016-0055-3
• Languages: English
• ISSNs: 2047-9158

Abstract

Abstract Background China has more cases of Alzheimer's disease (AD) than any other country in the world. As training to recognize and manage dementia is in its early stage, it is important to study clinicians' current prescription preferences for treating patients with AD. Methods This study surveyed neurologists, psychiatrists, and general physicians (GPs) in Shanghai who had outpatients with AD, using a questionnaire asking about their prescription preferences for these patients. Results Among the 148 clinicians in the study, 26.4 % were psychiatrists, 44.6 % were neurologists, and 29.1 % were GPs. The groups did not differ significantly in age, gender, or their monthly cases of new patients with mild or moderate AD (P > 0.05). Most clinicians prescribed Cholinesterase inhibitors (ChEIs), including Huperzine A, but there were significant group-differences in prescribing specific ChEIs (P < 0.05). The daily dosages of ChEI and Memantine prescribed by all three groups were small (P > 0.05), and all three groups prescribed piracetam, ergot, and ginkgo biloba drugs. All three groups also tended to treat AD patients with a combination of antidepressants and anxiolytics, although psychiatrists were significantly more likely than neurologists to combine antipsychotics with other drugs (P < 0.05). Conclusion Clinicians in Shanghai prescribed low doses of ChEIs and Memantine for patients with AD. A relatively high proportion also prescribed cognitive enhancers, which lack evidence-based support of their use, and antipsychotics. There is a need for more training about treating patients with AD and for clinicians to standardize their clinical practice.